CAS No.: 1092939-16-6
Ruxolitinib sulfate Catalog No. CSN17456
Synonyms: INCB018424 sulfate
Ruxolitinib sulfate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, > 130-fold selectivity for JAK1/2 versus JAK3.
| 规格 | 价格 | 促销价格 | 库存 | 数量 |
|---|
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
- 描述
- 临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点 NCT01319981 Leukemia Phase 2 Active, not recruiting December 2020 United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << NCT03117751 Acute Lymphoblastic Leukemia ... more >> Acute Lymphoblastic Lymphoma Collapse << Phase 2 Phase 3 Recruiting March 31, 2028 United States, Tennessee ... more >> St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Hiroto Inaba, MD, PhD 866-278-5833 referralinfo@stjude.org Principal Investigator: Hiroto Inaba, MD, PhD Collapse << NCT02723994 Leukemia Phase 2 Recruiting May 2024 - - 更多
- 参考文献
- [1] Verstovsek S, Mesa RA, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807.
- [2] Quintas-Cardama A, Vaddi K, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 Apr 15;115(15):3109-17.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 1092939-16-6 | 储存条件 |
|
|
| 分子式 | C17H20N6O4S | 运输 | 蓝冰 | |
| 分子量 | 404.44 | 别名 | INCB018424 sulfate |
